Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 9NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Prostatic Neoplasms 2Melanoma 2Lymphoma, Follicular 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1HTLV-I Infections 1HIV Infections 1Down Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 42Rituximab 40Vincristine 31Doxorubicin 29Prednisone 28Etoposide 27Filgrastim 22Peripheral Blood Stem Cell Transplantation 16Radiotherapy 12Ifosfamide 12Cytarabine 12Magnetic Resonance Spectroscopy 10Methotrexate 9Lenalidomide 8Cyclosporine 8Bortezomib 8fludarabine phosphate 7Vorinostat 7Specimen Handling 7Cisplatin 7Carboplatin 7tanespimycin 6ibrutinib 6Melphalan 6Gemcitabine 6Biopsy 6oblimersen 5alvocidib 5aldesleukin 5Oxaliplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × prednylidene × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
120 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡